PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-14.64%
Negative operating income growth while Healthcare median is -0.54%. Seth Klarman would check if structural or cyclical issues are at play.
-15.16%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
2.78%
EPS growth of 2.78% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
2.78%
Diluted EPS growth of 2.78% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
19.07%
Share change of 19.07% while Healthcare median is zero. Walter Schloss would see if the modest difference matters long-term.
19.07%
Diluted share change of 19.07% while Healthcare median is zero. Walter Schloss might see a slight difference in equity issuance policy.
-16.01%
Dividend cuts while Healthcare median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
-25.31%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-30.01%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2395.20%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
87.33%
OCF/share CAGR of 87.33% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
68.32%
3Y OCF/share growth of 68.32% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-1414.90%
Negative 10Y net income/share CAGR vs. Healthcare median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
92.17%
Net income/share CAGR of 92.17% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
80.18%
3Y net income/share CAGR of 80.18% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
1411.37%
Equity/share CAGR of 1411.37% while Healthcare median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-77.60%
Negative 5Y equity/share growth while Healthcare median is 3.50%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-28.05%
Negative 3Y equity/share growth while Healthcare median is 1.75%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.41%
Asset growth of 31.41% while Healthcare median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
13.37%
BV/share growth of 13.37% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-15.85%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
22.47%
R&D growth of 22.47% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-1.59%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.